JW Therapeutics announced the initiation of clinical study of Carteyva® for first-line treatment in patients with high-risk large B-cell lymphoma and the first patient infusion.
Bio-Thera Solutions, Ltd., a commercial-stage pharmaceutical company, announced that dosing has begun in a Phase 1 clinical study evaluating BAT8008, an antibody-drug conjugate that targets Trop2.
Tessa Therapeutics Ltd. announced entry into a Cooperative Research and Development Agreement with the U.S. National Cancer Institute, part of the National Institutes of Health, to investigate TT11X, Tessa’s allogeneic “off-the-shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell therapy, in multiple subtypes of non-Hodgkin lymphoma.
The past two decades were all about nucleic acid reading and writing. The next is about delivering DNA and RNA, Yogev Debbi, CEO of Mana.bio, told BioSpace in an interview.
Mainz Biomed NV, a molecular genetics diagnostic company specializing in the early detection of cancer, launches a number of events to raise awareness for the importance of early detection of colorectal cancer with physicians and medical professionals, but also with patients, their families, caregivers and the general public in Germany.
Antev Ltd., a late clinical-stage biotech company developing a novel gonadotrophin-releasing hormone antagonist, Teverelix trifluoroacetate, announces that the US Food & Drug Administration has provided written guidance on the company’s proposed Phase 3 pivotal trial design.
Cameras that can scan an entire body in a fraction of a second can give spinal surgeons an accurate assessment of how much range of motion youth with scoliosis have in their torso – a critical piece of information for guiding management of people with the condition, researchers at Hospital for Special Surgery in New
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration’s Office of Therapeutic Products has accepted the Company’s Biologics License Application resubmission for remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease.
Insurance lobbyists argue that the 1.03% plan increase is insufficient and, in combination with other changes, would actually result in payment cuts.
Medtronic’s device didn’t outperform competing systems being developed by J&J and Boston Scientific, but the results should be enough to secure FDA approval, one analyst wrote.
Medtronic’s pulsed field ablation device meets safety, efficacy metrics in trial Read More »
